Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
